Use of combined oral contraceptives (COCs)

Safety warnings | messages in brief | 06/06/2012

The occurrence of venous thromboembolic events (VTE) is a rare but long-known adverse effect of combined oral contraceptives (COCs), which is explicitly mentioned in the technical and instructions for use of the preparations. Recent studies have shown that the risk associated with drospirenone-containing preparations is significantly higher than originally assumed and probably similar to that of third-generation preparations. This was confirmed in a recent evaluation by the relevant European bodies.

The presence of one or multiple additional risk factors may constitute a contraindication for the use of COCs. The possible presence of a congenital increased tendency to coagulation (e.g., APC resistance) should also be considered. The prescription and selection of a suitable COC should always be made after careful anamnesis and consideration of the individual risk. This is especially true for new or first-time prescriptions.

Further information:

Information for the professional public, 10.04.2012.



Further inquiry note